Mark Wunderlich

12.1k total citations · 1 hit paper
92 papers, 4.3k citations indexed

About

Mark Wunderlich is a scholar working on Hematology, Molecular Biology and Immunology. According to data from OpenAlex, Mark Wunderlich has authored 92 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Hematology, 52 papers in Molecular Biology and 24 papers in Immunology. Recurrent topics in Mark Wunderlich's work include Acute Myeloid Leukemia Research (49 papers), Protein Degradation and Inhibitors (16 papers) and Histone Deacetylase Inhibitors Research (13 papers). Mark Wunderlich is often cited by papers focused on Acute Myeloid Leukemia Research (49 papers), Protein Degradation and Inhibitors (16 papers) and Histone Deacetylase Inhibitors Research (13 papers). Mark Wunderlich collaborates with scholars based in United States, China and France. Mark Wunderlich's co-authors include James C. Mulloy, Christopher R. Vakoc, Peter Valent, Jun Qi, Katharina Blatt, Johannes Zuber, Scott W. Lowe, Junwei Shi, Patrick A. Brown and Edward Allan R. Sison and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Mark Wunderlich

91 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

2011 1.4k citations Mark Wunderlich, James C. Mulloy et al. profile →

Peers

Countries citing papers authored by Mark Wunderlich

Since Specialization

Citations

This map shows the geographic impact of Mark Wunderlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Wunderlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Wunderlich more than expected).

Fields of papers citing papers by Mark Wunderlich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Wunderlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Wunderlich. The network helps show where Mark Wunderlich may publish in the future.

Co-authorship network of co-authors of Mark Wunderlich

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Wunderlich. A scholar is included among the top collaborators of Mark Wunderlich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Wunderlich. Mark Wunderlich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization 2025 ·Leukemia ·(unknown), Aishlin Hassan, Kwangmin Choi, (unknown), (unknown), Courtnee Clough, (unknown), Kathleen Hueneman, Lyndsey Bolanos, Mark Wunderlich, Xiaohu Zhang, Crystal McKnight, Michele Ceribelli, David O. Holland, Carleen Maitland, Kenneth D. Greis, Craig J. Thomas, Daniel T. Starczynowski	2
2	Ubiquitin-conjugating enzyme UBE2N modulates proteostasis in immunoproteasome-positive acute myeloid leukemia 2025 ·Journal of Clinical Investigation ·(unknown), Laura Barreyro, (unknown), Kathleen Hueneman, (unknown), (unknown), Issac Choi, Lyndsey Bolanos, Mark Wunderlich, Andrew Volk, Stephanie S. Watowich, Kenneth D. Greis, Daniel T. Starczynowski	4
3	Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia 2024 ·Cancers ·(unknown), Ola A. Elgamal, Mark Wunderlich, (unknown), (unknown), (unknown), (unknown), (unknown), Jianmin Pan, (unknown), Megan Johnstone, Amina Abdul‐Aziz, (unknown), N. Shesh, John C. Byrd, Erin Hertlein	1
4	Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis 2024 ·Nature Communications ·(unknown), Aishlin Hassan, Kathleen Hueneman, (unknown), Averil Ma, (unknown), Eric O’Brien, Mark Wunderlich, John P. Perentesis, Daniel T. Starczynowski	8
5	Repression of TRIM13 by chromatin assembly factor CHAF1B is critical for AML development 2023 ·Blood Advances ·(unknown), (unknown), Xiaoqin Zhu, (unknown), (unknown), (unknown), (unknown), Michael A. Wyder, Nathan Salomonis, Mark Wunderlich, Kenneth D. Greis, Daniel T. Starczynowski, Andrew Volk	4
6	In vivo development of immune tissue in human intestinal organoids transplanted into humanized mice 2023 ·Nature Biotechnology ·Carine Bouffi, Kathryn A. Wikenheiser‐Brokamp, Praneet Chaturvedi, Nambirajan Sundaram, (unknown), Mark Wunderlich, Nicole Brown, Janet F. Staab, Rachel Latanich, Nicholas C. Zachos, Emily M. Holloway, Maxime M. Mahé, Holly M. Poling, (unknown), (unknown), Jason R. Spence, James C. Mulloy, Aaron M. Zorn, James M. Wells, Michael A. Helmrath	76
7	Kinase-independent role of mTOR and on-/off-target effects of an mTOR kinase inhibitor 2023 ·Leukemia ·(unknown), Mark Wunderlich, Xiongwei Cai, (unknown), Feng Zhang, Ashley Kuenzi Davis, (unknown), Fukun Guo, Q. Richard Lu, Mohammad Azam, Weidong Tian, Yi Zheng	3
8	Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML 2023 ·Blood ·(unknown), (unknown), Puneet Agarwal, Jennifer Yeung, (unknown), (unknown), (unknown), Lyndsey Bolanos, Kathleen Hueneman, Mark Wunderlich, (unknown), Kwangmin Choi, Andrew Volk, Kenneth D. Greis, Jan S. Rosenbaum, Scott B. Hoyt, Craig J. Thomas, Daniel T. Starczynowski	27
9	Momelotinib is a highly potent inhibitor of FLT3-mutant AML 2021 ·Blood Advances ·Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani, (unknown), Mark Wunderlich, Tahir Latif, Daniel T. Starczynowski, Mohammad Azam	15
10	The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia 2021 ·Leukemia ·(unknown), (unknown), Kathleen Hueneman, (unknown), (unknown), (unknown), (unknown), Lyndsey Bolanos, (unknown), Kwangmin Choi, Mark Wunderlich, John P. Perentesis, Timothy M. Chlon, Marie–Dominique Filippi, Daniel T. Starczynowski	25
11	Development and characterization of a DNA aptamer for MLL-AF9 expressing acute myeloid leukemia cells using whole cell-SELEX 2021 ·Scientific Reports ·(unknown), Erin M. McConnell, Eman M. Hassan, Mark Wunderlich, (unknown), (unknown), Melissa J. Chee, James C. Mulloy, William G. Willmore, Maria C. DeRosa, Edward J. Merino	13
12	Asymmetrically Segregated Mitochondria Provide Cellular Memory of Hematopoietic Stem Cell Replicative History and Drive HSC Attrition 2020 ·Cell stem cell ·Ashwini Hinge, Jingyi He, (unknown), José Javier, Juying Xu, (unknown), Hiromi Sesaki, Tingyu Li, Jie Yu, Mark Wunderlich, James C. Mulloy, Matthew Kofron, Nathan Salomonis, H. Leighton Grimes, Marie-Dominique Filippi	112
13	Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia 2019 ·Nature Communications ·Yasutaka Hayashi, Susumu Goyama, (unknown), (unknown), Shuhei Asada, Yosuke Tanaka, Tomofusa Fukuyama, Mark Wunderlich, Eric O’Brien, Benjamin Mizukawa, Satoshi Yamazaki, Akiko Matsumoto, Satoshi Yamasaki, Tatsuhiro Shibata, Koichi Matsuda, Goro Sashida, Hitoshi Takizawa, Toshio Kitamura	33
14	A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic stem cells 2018 ·Leukemia ·Wei Du, Wei Liu, Benjamin Mizukawa, Xun Shang, (unknown), Mark Wunderlich, Hartmut Geiger, Stella M. Davies, James C. Mulloy, Qishen Pang, Yi Zheng	9
15	Improved multilineage human hematopoietic reconstitution and function in NSGS mice 2018 ·PLoS ONE ·Mark Wunderlich, Fu‐Sheng Chou, (unknown), Pietro Presicce, Claire Chougnet, Júlio Aliberti, James C. Mulloy	68
16	PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of B-Cell Acute Lymphoblastic Leukemia 2017 ·Blood ·Mark Wunderlich, Nicole Manning, (unknown), (unknown), Benjamin Mizukawa, James C. Mulloy	1
17	Design of a hydrogen peroxide-activatable agent that specifically targets cancer cells 2014 ·Bioorganic & Medicinal Chemistry ·(unknown), (unknown), Mark Wunderlich, (unknown), Julio A. Landero Figueroa, James C. Mulloy, (unknown)	18
18	Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells 2013 ·Journal of Clinical Investigation ·Susumu Goyama, (unknown), Lea Cunningham, Yue Zhang, (unknown), Nahoko Nishimoto, Masahiro Nakagawa, André Olsson, Mark Wunderlich, Kevin A. Link, Benjamin Mizukawa, H. Leighton Grimes, Mineo Kurokawa, (unknown), Gang Huang, James C. Mulloy	151
19	Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome 2013 ·Cancer Cell ·Garrett W. Rhyasen, Lyndsey Bolanos, Jing Fang, Andrés Jerez, Mark Wunderlich, Carmela Rigolino, Lesley Mathews, Marc Ferrer, Noel Southall, Rajarshi Guha, Jonathan M. Keller, Craig J. Thomas, Levi J. Beverly, Agostino Cortelezzi, Esther N. Oliva, Maria Cuzzola, Jaroslaw P. Maciejewski, James C. Mulloy, Daniel T. Starczynowski	155
20	DNA Methylation Profiles and Their Relationship with Cytogenetic Status in Adult Acute Myeloid Leukemia 2010 ·PLoS ONE ·Sara Álvarez, Javier Suela, Ana Valencia, Agustín F. Fernández, Mark Wunderlich, Xabier Agirre, Felipe Prósper, José I. Martı́n-Subero, Alba Maiqués-Díaz, Francesco Acquadro, Sandra Rodríguez, Marı́a José Calasanz, José Román‐Gómez, Reiner Siebert, James C. Mulloy, José Cervera, Miguel Á. Sanz, Manel Esteller, Juan C. Cigudosa	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact